Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
In patients with metastatic renal cell cancer, the overall response rate to immunotherapy appears to remain consistent regardless of the line of therapy. This is the finding of Steven Yip, MD, of the University of Calgary, and colleagues, who presented their results at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4580).
Dr. Yip and his team conducted a retrospective analysis of patients with metastatic renal cell carcinoma, based on the rationale that treatment outcomes with checkpoint inhibitors in this patient population are poorly characterized in the real-world setting. Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), they evaluated 312 patients with metastatic renal cell cancer who were treated with 1 or more lines of immunotherapy, with or without a targeted agent.
In evaluable patients, the overall response rate to immunotherapy was 29% (32% in the first-line, 22% in the second-line, 33% in the third-line, and 32% in the fourth-line setting). In the second-line, IMDC criteria appeared to appropriately stratify patients into favorable-, intermediate-, and poor-risk groups, but in contrast to the clinical trial data, longer duration of treatment is typically observed in real-world practice, they noted. Furthermore, they concluded, patient age did not appear to be a factor influencing the duration of treatment.